proctor and gamble case analysis

Upload: surya-bakshi

Post on 02-Jun-2018

222 views

Category:

Documents


0 download

TRANSCRIPT

  • 8/10/2019 Proctor and Gamble Case Analysis

    1/3

    Proctor & Gamble Inc. Case Analysis

    Problem Statement

    In what ways can Gwen Hearst develop a strategy to ensure continued profitability of Scope, the

    mouthwash brand of P&G, under the threat posed by the new competition in the Canadian market.

    Introduction

    P&G is one of the most successful consumer goods company in the world. In 1990, its Canadian

    subsidiary was a major business unit and contributed $1.4 billion in the sales and $100 million in net

    earnings. The case here discusses the scenario in 1990 when one of its key products, Scope, the

    mouthwash brand was exposed to a competitive threat due to the unique market positioning by its

    competitor brand Plax. Since its introduction in 1988, Plax had gained a 10% share in the category

    and was a cause of concern to the management. The brand manager, Hearst, was responsible for

    maximising the market share, volume and profitability of the brand and was expected to come up with

    a strategy to ensure the same.

    After analysing the situation of the market she had three alternatives in her mind.

    1) Introducing a new line of product

    2) Repositioning existing brand in lines with the competitors

    3) Maintaining status-quo

    Scope:

    Scope was introduced in 1967 by P&G. Prior to Scope the market was dominated by Listerine, the

    first mouthwash developed by Warner-Lambert which had a medicinal taste. P&G saw an opportunity

    here and came up with the brand Scope that was positioned as a great-tasting mouth-refreshing brand

    that provided bad breath protection. It was the first brand that offered better taste than other

    mouthwashes in addition to the bad breath protection. Scope was a market leader with 32.3% with therest of the brands nowhere close to this number. The market was further divided into food stores and

    drug store outlets wherein its market share in food store accounted for 42% and that in Drug Stores

    accounted for a 27%. As mentioned in the case, Scope had not been targeting the drug store category

    as the brand was positioned as more of a cosmetic product rather than a drug product. The spending

    on the advertising and media plans were comparatively higher than the rest of the brands but had

    resulted in lower GRPs indicating a revision in the plans. The retail indices also showed the product to

    be pocket friendly.

    The Entry of Plax:

    Plax was introduced in 1988 by Pfizer Inc. with a different platform altogether. It was promoted as apre-brushing rinse formula that claimed to remove up to three times more plaque than brushing alone.

    The company invested $4 million in extensive advertising and sales promotion campaign during the

    launch which resulted in a 10% market share by 1990. There was a flawed advertisement mentioned

    in the case that highlights the exaggeration made by the brand about the plaque protection. However

    due to the brand new segmentation of the product and addressing to the fact that a major chunk of

    Canadian population suffered from the plaque and gingivitis problems, Plax penetrated into the

    market in no time. Plax was priced at a higher level in food store while at a premium in drug store

    signifying its medicinal value.

  • 8/10/2019 Proctor and Gamble Case Analysis

    2/3

    Assessment of available alternatives:

    1. Introducing new line of product

    This involved several steps and heavy investment in the form of R&D and promotions. To compete

    with Plax, the company has an option of launching a new product line in drug category instead of the

    present cosmetic category in which Scope was selling. This would involve additional approval by

    regulatory authority and also advertisement scrutiny henceforth.

    Also it was estimated to cannibalise 2 to 9percent of Scopes sales. In the discussion with various

    departments various data were put forth. The product development department (PDD) were of the

    opinion that a product test of $20,000 would be required which might not be justifiable as the product

    they could offer was only equal to that of Plax if not higher with only different being that it would

    provide a better taste.

    Various costs including capital cost, marketing cost, delivery cost, inventory cost, ingredients cost and

    other important costs which create concern and would also require effective strategic management.

    There was also a concern on number of units sold as it might lead to additional listing fee by the

    retailers. The market research conducted by P&G had shown no significant increase in market share

    with the introduction of the new product.

    Another problem that was anticipated was with respect to the name of the new product. They had to

    decide whether the new product will be launched under the name of Scope or with a different name.

    Introducing the product in the same name may lead to loyal customers getting confused because of the

    new brand image and stopping to use Scope.

    2. Re-positioning the present brand

    The brand Scope already enjoyed a loyal customer base. If this was changed then the customercurrently buying the product to get rid of bad breath (40% of the total consumer) might switch to

    some other product leading to a decrease in sales. To avoid this if there was an ad campaign done to

    cater the product as serving both the purposes it would be difficult to be projected with equal

    importance putting consumers in a fix.

    Further, the product will change from the category of Cosmetics to Drug. This will lead to increase in

    scrutiny of advertisement with guidelines that may be stringent but at the same time it will prevent the

    current consumers from switching to other brands although it will not lead to an increase in the

    product growth. Further, there would be significant cost involved in promoting the revised product

    along with an increase in its ingredients costs and re-packaging costs.

    3. Maintaining the Status-quo

    A few departments were of the view that there was actually no real threat existing as Plax was

    positioned very differently in comparison to Scope. However, the sales people had different view.

    They had seen the inroads Plax had been making in the marketplace and were of the view that Scope

    should respond quickly.

  • 8/10/2019 Proctor and Gamble Case Analysis

    3/3

    Our Recommendation

    We recommend the company to go for re-positioning of its brand and not start a separate line

    of extension or maintain a status quo. The various reasons supporting it are as follows:

    a. The brand is being positioned as a cosmetic product which helps to fight bad breath

    but as per Exhibit 3, only the consumers are able to find the product to perform above

    average in that attribute whereas other users does not find the advertisements or

    promotions that impactful in its positioning and even rated it below average in other

    attributes. Thus, the brand needs a lot of improvement in its advertising and

    promotion campaign to help it build its brand image better.

    b. Since 65 percent of the sale of all mouthwash happens in drug store, the company

    needs to ensure that it targets the drug store more than the food store. Another reason

    for the same being that the 42 percent of the sale of Scope is already from food store

    and therefore it does not need to anything in case of food store.

    c. The case also points out that even if the company launches a new product, it is not

    sure if it will be a success since the new product that is proposed to be launched

    launch will be no different from that of Plax and will be not accepted well with theretailers and can lead to extra costs to put the stock with them and also might lead to

    loss to its own brand Scope due to lesser exposure.

    d. Product Development Department of Scope is of the view that Scope reduces Plaque

    as well. However, they do not have any clinical evidence to extend this claim. The

    company, therefore, should try to get its claim tested by the respective agency and

    extend the same. This will be an added advantage to them. It although may not

    generate additional sales but it can definitely prevent current users from switching

    over to other brand.

    e.

    We find that the advertising agency is not very much in favour of making any newclaims for Scope as it may create a confusion among the customers. Moreover, it will

    be difficult for them to send out two different ideas in the same commercial. However

    this should not be a hindrance as there are several products in the market that perhaps

    states multiple claims and still does well. It basically all depends on effective

    advertising. Moreover the market research carried out had already stated that the

    current consumer will not switch over to other brand if any additional claim is made.

    ----

    Prepared and Submitted by

    Group AC2